ESR2 and non-small cell lung carcinoma: Estrogens are known to stimulate non–small cell lung cancer (NSCLC) cell proliferation, whereas the antiestrogen fulvestrant inhibits this effect.[6] Cellular responses to estrogens are mediated by 2 distinct receptors, ERa and ERβ.